SCHEMBL1847401

SCHEMBL1847401

FC(F)(F)c1ccc(C2CC2)cc1

nearest known ligand 0.73

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 5/20 0.73
MAOB P27338 3/20 0.42
KDM1A O60341 2/20 0.42
MAOA P21397 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Cyanide SCHEMBL27770959 0.93 HTR2C (0.66) HTR2CMAOBKDM1A
Dimethylamine SCHEMBL27903575 0.91 HTR2C (0.63) HTR2CMAOBKDM1A
SCHEMBL5147805 0.91 HTR2C (0.68) HTR2CKDM1A
SCHEMBL2539686 0.91 HTR2C (0.68) HTR2CKDM1A
SCHEMBL23484594 0.89 HTR2C (0.61) HTR2C
SCHEMBL8597879 0.89 HTR2C (0.61) HTR2CMAOBKDM1A
SCHEMBL8597881 0.89 HTR2C (0.61) HTR2CMAOBKDM1AMAOA
SCHEMBL13197432 0.89 HTR2C (0.61) HTR2CKDM1A
SCHEMBL8597880 0.89 HTR2C (0.61) HTR2CMAOBKDM1A
SCHEMBL31263 0.89 HTR2C (0.61) HTR2CKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112812133-B Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2022-03-11 CN claimed
CN-112812133-A Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2021-05-18 CN claimed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US claimed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO claimed
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF VENTUS THERAPEUTICS U S INC (US) 2026-01-08 US disclosed
CN-112812133-B Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2022-03-11 CN disclosed
US-11021427-B2 Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids THE SCRIPPS RESEARCH INSTITUTE (US) 2021-06-01 US disclosed
CN-112812133-A Alpha, alpha-difluoroallyl organometallic compound and preparation method and application thereof 南京工业大学 2021-05-18 CN disclosed
WO-2021078995-A1 SELECTIVE POLYPEPTIDE SYNTHESIS STALLING ASSAY AND COMPOUND UMC UTRECHT HOLDING B.V. (NL) 2021-04-29 WO disclosed
EP-3811945-A1 COMPOUNDS FOR TREATING AND PREVENTING GROWTH HORMONE RECEPTOR-DEPENDENT CONDITIONS UMC Utrecht Holding B.V. (NL) 2021-04-28 EP disclosed
US-10821100-B2 Triazolone compounds as mPGES-1 inhibitors Ichnos Sciences SA (CH) 2020-11-03 US disclosed
WO-2019204477-A1 PD(II)-CATALYZED ENANTIOSELECTIVE C-H ARYLATION OF FREE CARBOXYLIC ACIDS THE SCRIPPS RESEARCH INSTITUTE (US) 2019-10-24 WO disclosed
WO-2010010154-A1 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2010-01-28 WO disclosed
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS WYETH (US) 2007-12-27 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
US-20070287699-A1 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-12-13 US disclosed
WO-2007130499-A2 ANTIVIRAL AGENTS VIROBAY, INC. (US) 2007-11-15 WO disclosed
US-20070259936-A1 Benzimidazole Modulators of VR1 JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-08 US disclosed
CN-101012184-A Fluorine-containing cyclopropane and synthetic method thereof UNIV SHANGHAI (CN) 2007-08-08 CN disclosed
EP-0832073-B1 QUINAZOLINES AND PHARMACEUTICAL COMPOSITIONS SUGEN INC (US) 2002-01-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299072-A1 KV1.5 POTASSIUM CHANNEL INHIBITORS KCNA5, KCNH1, KCNK5 HTR2C 3081/4885MAOB 2969/4885KDM1A 196/4885
US-20070259936-A1 Benzimidazole Modulators of VR1 VRK1, VRK2, VIL1 HTR2C 371/4885MAOB 2944/4885KDM1A 1102/4885
US-20070287699-A1 ANTIVIRAL AGENTS EIF2AK2, MAVS, ZC3HAV1 HTR2C 4453/4885MAOB 3428/4885KDM1A 4133/4885
US-11021427-B2 Pd(II)-catalyzed enantioselective C—H arylation of free carboxylic acids PDCD1, PDK3, PDCD1LG2 HTR2C 770/4885MAOB 222/4885KDM1A 1577/4885
US-20260007684-A1 AMIDE DERIVATIVES FOR INHIBITING NLRP3 AND USES THEREOF NOD1, NLRP3, NOD2 HTR2C 1515/4885MAOB 2926/4885KDM1A 4256/4885
US-10821100-B2 Triazolone compounds as mPGES-1 inhibitors PTGES, PTGS1, PTGIS HTR2C 653/4885MAOB 300/4885KDM1A 2981/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.